IL-6 Antagonist Formulations Stabilizing Isoforms via pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic compositions for interleukin-6 (IL-6) antagonists face challenges in stability and efficacy, particularly in maintaining effective concentrations and isoform distribution for optimal therapeutic outcomes in treating IL-6-associated disorders.
Innovation Solution
Development of stable aqueous pharmaceutical formulations containing IL-6 antagonists, such as IL-6 antibodies or fragments, with specific concentration ranges and combinations of buffering agents, surfactants, and tonicity agents, optimized for pH and stability to ensure prolonged effectiveness and reduced systemic leakage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic compositions for IL-6 antagonists are used, then the formulations can deliver the antagonist, but they face challenges in stability and efficacy, particularly in maintaining effective concentrations and isoform distribution
Solution Approach 1:
The patent applies parameter changes by optimizing the pH of the formulation to specifically maintain the IgG2-A and IgG2-A/B isoforms. By adjusting the pH parameter within a specific range, the formulation stabilizes the desired isoform distribution while preventing degradation to other isoforms, thereby resolving the contradiction between reliability and composition stability.
Solution Approach 2:
The patent employs composite materials by formulating a complex aqueous composition containing multiple components: IL-6 antagonist (5-50 mg/ml), buffering agent (10-50 mM), surfactant (0.01%-1%), and tonicity agent (1%-10%). This composite formulation works synergistically to maintain both stability and isoform distribution, where each component contributes to different aspects of formulation performance.
2Productivity
If higher concentrations of IL-6 antagonist are used to enhance therapeutic efficacy, then the treatment effectiveness improves, but the formulation stability and isoform distribution become more difficult to maintain
Solution Approach 1:
The patent utilizes parameter changes by establishing an optimized concentration range for the IL-6 antagonist (5-50 mg/ml) and coordinating it with specific pH conditions. This parameter optimization allows the formulation to maintain high therapeutic efficacy while preserving formulation stability and isoform distribution, avoiding the pitfalls of both too low and excessively high concentrations.
Solution Approach 2:
The buffering agent serves as an intermediary component that mediates between the IL-6 antagonist concentration and formulation stability. The buffering agent (10-50 mM) maintains pH within the optimal range, thereby protecting the IL-6 antagonist from degradation even at higher concentrations, and ensuring stable isoform distribution throughout the therapeutic concentration range.
3Duration of action of moving object
If the formulation is designed for prolonged effectiveness, then the duration of action increases, but the complexity of maintaining stability at varying temperatures increases
Solution Approach 1:
The patent employs composite materials by incorporating a multi-component formulation system that collectively provides temperature resilience. The combination of IL-6 antagonist, buffering agent, surfactant, and tonicity agent creates a synergistic system that maintains formulation integrity across varying temperatures, enabling prolonged effectiveness without excessive complexity in temperature control requirements.
Solution Approach 2:
The formulation exhibits self-service characteristics through its inherent buffering capacity and stabilizing components that automatically maintain pH and isoform distribution without external intervention. The buffering agent and surfactant work autonomously to protect the IL-6 antagonist from temperature-induced degradation, reducing the need for complex external temperature control mechanisms while preserving prolonged effectiveness.
Data Source
AI summary
Featured herein are pharmaceutical compositions and formulations containing an interleukin-6 (IL-6) antagonist, e.g., an IL-6 antibody molecule, designed for administration for a subject. The pharmaceutical compositions and formulations provided herein are suitable for use in manufacture of medicaments or methods of treating subjects with IL-6 associated diseases, e.g., ocular diseases associated with elevated levels of IL-6.